Teduglutide seems to be a safe and effective treatment for pediatric short bowel syndrome (SBS) based on a study of 17 pediatric patients treated with teduglutide. 12 out of 17 patients achieved independence from parenteral nutrition, with 3 patients weaning after 3 months, 4 after 6 months, and 5 after 12 months. Teduglutide treatment also decreased parenteral nutrition requirements by 50% in most other patients. Only one patient did not see improvements. Adverse effects were generally mild, with one episode each of cholecystitis and cardiac decompensation in patients with pre-existing conditions.